Keenova Therapeutics plc

8-K · tm2616735d1_8k.htm iXBRL

0001567892

 2026-06-02
 2026-06-02

 iso4217:USD

 xbrli:shares

 iso4217:USD

 xbrli:shares

  

  

  

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

  

  

 FORM  8-K

  

  

 CURRENT REPORT

 Pursuant to Section 13 or
 15(d) 

   of the   Securities Exchange
Act of 1934

  

 Date of Report (Date of earliest event reported):
 June 2, 2026

  

  

 Keenova Therapeutics plc

 (Exact name of registrant as specified in its
charter)

  

  
  
  

 Ireland
 001-35803
 98-1088325

 (State or other jurisdiction

 of incorporation)
 (Commission

 File Number)
 (IRS Employer

 Identification No.)

  
  
  

  

 College Business & Technology Park , Cruiserath ,
 Blanchardstown , Dublin 15 , Ireland

 (Address
of principal executive offices)

  

 + 353 1 6960000

 (Registrant’s telephone number, including
area code)

  

  

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  

 ¨
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  
  

 ¨
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  
  

 ¨
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  
  

 ¨
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 Securities registered pursuant to Section 12(b) of the Act:
None

  

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  

 Emerging growth company   ¨

  

 If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨

  

  

  

  

 Item 5.07.
 Submission of Matters to a Vote of Security Holders.

  

 Each of the items listed below
was submitted to a vote of shareholders at the 2026 Annual General Meeting of Shareholders (the “2026 AGM”) on June 2, 2026
and is described in more detail in Keenova Therapeutics plc’s (the “Company”) definitive proxy statement for the 2026
AGM, filed by the Company with the U.S. Securities and Exchange Commission on April 27, 2026. The final results for each of the matters
submitted to a vote of shareholders are as follows:

  

 Proposal 1: By separate
resolutions, to elect as directors and to hold office, expiring at the end of the Company’s Annual General Meeting of Shareholders
in 2027 (the “2027 AGM”), the following individuals:

  

  
  
 FOR
  
  
 AGAINST
  
  
 ABSTAIN
  
  
 BROKER

 NON-VOTES
  

 Paul M. Bisaro
  
 25,282,713
  
  
 8,884
  
  
 191,295
  
  
 310,829
  

 Leslie Donato
  
 25,291,597
  
  
 0
  
  
 191,295
  
  
 310,829
  

 Katina Dorton
  
 25,291,597
  
  
 0
  
  
 191,295
  
  
 310,829
  

 Paul Efron
  
 25,162,447
  
  
 84,006
  
  
 236,439
  
  
 310,829
  

 Scott Hirsch
  
 25,176,548
  
  
 72,773
  
  
 233,571
  
  
 310,829
  

 Sophia Langlois
  
 25,265,940
  
  
 25,657
  
  
 191,295
  
  
 310,829
  

 Sigurdur O. Olafsson
  
 25,285,209
  
  
 6,388
  
  
 191,295
  
  
 310,829
  

 Marc Yoskowitz
  
 25,272,285
  
  
 19,312
  
  
 191,295
  
  
 310,829
  

 Jonathan Zinman
  
 25,265,940
  
  
 25,657
  
  
 191,295
  
  
 310,829
  

  

 Each of the foregoing nominees
was elected to hold office until the conclusion of the 2027 AGM or until his or her earlier death, resignation or removal.

  

 Proposal 2: Advisory non-binding
vote to approve the re-appointment of PricewaterhouseCoopers LLP as the independent auditors of the Company and, by binding vote, to authorize
the Audit Committee of the Board of Directors to set the independent auditors’ remuneration.

  

 FOR
  
  
 AGAINST
  
  
 ABSTAIN
  
  
 BROKER

 NON-VOTES
  

 25,602,426
  
  
 0
  
  
 191,295
  
  
 0
  

  

 Proposal 3: Advisory non-binding
vote to approve the Company’s executive compensation.

  

 FOR
  
  
 AGAINST
  
  
 ABSTAIN
  
  
 BROKER

 NON-VOTES
  

 24,965,301
  
  
 326,296
  
  
 191,295
  
  
 310,829
  

  

 Proposal 4: Advisory non-binding
vote to approve the frequency of future advisory non-binding votes to approve the Company’s executive compensation.

  

 1 YEAR
  
  
 2 YEARS
  
  
 3 YEARS
  
  
 ABSTAIN
  
  
 BROKER

 NON-VOTES
  

 25,117,919
  
  
 172,952
  
  
 726
  
  
 191,295
  
  
 310,829
  

  

 In light of the results of Proposal
4, and consistent with the Board of Directors’ recommendation, the Company intends to continue to include an advisory non-binding
vote to approve the Company’s executive compensation in its proxy materials annually until the next required vote on the frequency
of future advisory non-binding votes to approve the Company’s executive compensation.

  

 Proposal 5: Approve the
reduction of Company capital (Special Resolution).

  

 FOR
  
  
 AGAINST
  
  
 ABSTAIN
  
  
 BROKER

 NON-VOTES
  

 25,256,218
  
  
 35,379
  
  
 191,295
  
  
 310,829
  

  

 Proposal 6: Approve an
amendment to the Company’s articles of association (Special Resolution).

  

 FOR
  
  
 AGAINST
  
  
 ABSTAIN
  
  
 BROKER

 NON-VOTES
  

 25,476,547
  
  
 6,345
  
  
 0
  
  
 310,829
  

  

  

  

  

 SIGNATURES

  

 Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  
 KEENOVA THERAPEUTICS PLC

  
 (registrant)

  
  
  

  
 By:
 /s/ Mark Tyndall

  
  
 Mark Tyndall

  
  
 Executive Vice President, Chief Legal Officer &
 Corporate Secretary

  

 Date: June 3, 2026